KR101912982B1 - 세포자멸사-신호전달 내성 세포를 선택하기 위한 디바이스 및 방법, 그리고 그의 용도 - Google Patents

세포자멸사-신호전달 내성 세포를 선택하기 위한 디바이스 및 방법, 그리고 그의 용도 Download PDF

Info

Publication number
KR101912982B1
KR101912982B1 KR1020147027817A KR20147027817A KR101912982B1 KR 101912982 B1 KR101912982 B1 KR 101912982B1 KR 1020147027817 A KR1020147027817 A KR 1020147027817A KR 20147027817 A KR20147027817 A KR 20147027817A KR 101912982 B1 KR101912982 B1 KR 101912982B1
Authority
KR
South Korea
Prior art keywords
cells
apoptosis
cell
another embodiment
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147027817A
Other languages
English (en)
Korean (ko)
Other versions
KR20150011796A (ko
Inventor
샤이 야르코니
나디르 아스케나시
Original Assignee
셀렉트 바이오테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀렉트 바이오테라퓨틱스 리미티드 filed Critical 셀렉트 바이오테라퓨틱스 리미티드
Publication of KR20150011796A publication Critical patent/KR20150011796A/ko
Application granted granted Critical
Publication of KR101912982B1 publication Critical patent/KR101912982B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
KR1020147027817A 2012-03-06 2013-03-05 세포자멸사-신호전달 내성 세포를 선택하기 위한 디바이스 및 방법, 그리고 그의 용도 Expired - Fee Related KR101912982B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607033P 2012-03-06 2012-03-06
US61/607,033 2012-03-06
PCT/IL2013/000026 WO2013132477A1 (en) 2012-03-06 2013-03-05 Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof

Publications (2)

Publication Number Publication Date
KR20150011796A KR20150011796A (ko) 2015-02-02
KR101912982B1 true KR101912982B1 (ko) 2018-10-29

Family

ID=49116028

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147027817A Expired - Fee Related KR101912982B1 (ko) 2012-03-06 2013-03-05 세포자멸사-신호전달 내성 세포를 선택하기 위한 디바이스 및 방법, 그리고 그의 용도

Country Status (11)

Country Link
US (2) US9783778B2 (enExample)
EP (2) EP2823040B1 (enExample)
JP (1) JP6429191B2 (enExample)
KR (1) KR101912982B1 (enExample)
CN (2) CN104245924B (enExample)
AU (1) AU2013229008B2 (enExample)
CA (1) CA2866358C (enExample)
DK (1) DK2823040T3 (enExample)
IL (1) IL234459B (enExample)
RU (1) RU2630301C2 (enExample)
WO (1) WO2013132477A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016116732A (ru) * 2013-10-09 2017-11-15 Сэллект Байотерапьютикс Лтд. Активация гемопоэтических клеток-предшественников путем предтрансплантационного воздействия лигандами рецепторов смерти
WO2016193986A2 (en) 2015-06-05 2016-12-08 Cellect Biotherapeutics Ltd. Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof
JP2021534747A (ja) * 2018-08-22 2021-12-16 セレクト バイオセラピューティクス リミテッド アポトーシス感受性細胞のモジュレーション
US20220002363A1 (en) * 2020-07-03 2022-01-06 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating pulmonary disease

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS61235752A (ja) 1985-04-11 1986-10-21 Asahi Optical Co Ltd 細胞分離材、分離器および分離方法
IT8523298V0 (it) * 1985-10-02 1985-10-02 Pierrel Hospital Spa Catetere venoso centrale.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4979959A (en) 1986-10-17 1990-12-25 Bio-Metric Systems, Inc. Biocompatible coating for solid surfaces
US4885234A (en) 1988-09-29 1989-12-05 Eastman Kodak Company Photographic materials containing stable cyan coupler formulations
US5998024A (en) 1995-02-02 1999-12-07 Rainer H. Frey Biocompatible material and method of manufacture and use thereof
EA002819B1 (ru) 1997-05-14 2002-10-31 Авентис Фармасьютикалз Продактс Инк. Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция
US6040182A (en) 1997-11-12 2000-03-21 Becton Dickinson And Company Method and materials for efficiency protein immobilization on tissue culture treated assay plates
GB9724270D0 (en) 1997-11-17 1998-01-14 Babraham The Inst Methods and means for mutagenesis of dna
EP1076635B1 (en) 1998-04-22 2002-03-06 St. Jude Medical AB Biocompatible material for implants
US20010049115A1 (en) * 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
US20090130718A1 (en) 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
WO2003002761A1 (en) 2001-06-29 2003-01-09 Novozymes A/S Method of multimerization and site-directed mutagenesis
US20030044389A1 (en) 2001-07-02 2003-03-06 Brown Patrick O. Microarrays for cell phenotyping and manipulation
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
ATE519115T1 (de) * 2002-06-13 2011-08-15 Merck Patent Gmbh Verfahren für die identifizierung von allo- antigenen und ihre verwendung für krebstherapie und transplantation
US20040115216A1 (en) * 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
US20060009623A1 (en) 2004-07-06 2006-01-12 National University Of Singapore C-terminal attachment of ligands to proteins for immobilization onto a support
US20080241109A1 (en) * 2004-10-01 2008-10-02 Marc Dupuis Method for Ex-Vivo Purging in Autologous Transplantation
US8252587B2 (en) * 2004-10-25 2012-08-28 Celerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
DE602005008265D1 (de) * 2005-12-23 2008-08-28 Biedermann Motech Gmbh Flexible Stabilisierungsvorrichtung zur dynamischen Stabilisierung von Knochen oder Wirbeln
CA2653881C (en) * 2006-05-31 2016-08-23 Styx Llc Methods of selecting stem cells and uses thereof
CN101517070A (zh) * 2006-05-31 2009-08-26 Styx有限责任公司 选择干细胞的方法及其用途
AU2008229636B2 (en) * 2007-03-16 2014-08-14 Qiagen Sciences Llc A cell-mediated immune response assay and kits therefor
KR100920729B1 (ko) 2007-10-01 2009-10-07 한국생명공학연구원 펩타이드 혼성체를 사용한 배향성이 조절된 항체단분자막의 제조방법
WO2009154840A2 (en) 2008-03-27 2009-12-23 Neostem, Inc. Compositions and methods using stem cells in cutaneous wound healing
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
EP2282786B1 (en) 2008-06-13 2015-10-28 Smith & Nephew, Inc. Fixation devices for tissue repair
WO2010051032A1 (en) * 2008-10-31 2010-05-06 Synthes Usa, Llc Method and device for activating stem cells
GB0823553D0 (en) 2008-12-24 2009-01-28 Immunosolv Ltd Cell separation technique
JP5327457B2 (ja) * 2009-03-27 2013-10-30 セイコーエプソン株式会社 がん細胞分離装置およびその製造方法
JP2010227313A (ja) * 2009-03-27 2010-10-14 Seiko Epson Corp がん細胞除去システムおよびがん細胞除去装置
EP2595637B1 (en) * 2010-07-22 2017-11-01 Cellect Biotherapeutics Ltd. Regulatory immune cells with enhanced targeted cell death effect

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular Therapy 13(1) May 2006 Abstract #1041 page S399

Also Published As

Publication number Publication date
CN109116033A (zh) 2019-01-01
JP2015510758A (ja) 2015-04-13
CN104245924B (zh) 2020-05-01
JP6429191B2 (ja) 2018-11-28
CA2866358C (en) 2020-06-23
RU2630301C2 (ru) 2017-09-06
EP3486315A1 (en) 2019-05-22
EP2823040B1 (en) 2018-08-01
KR20150011796A (ko) 2015-02-02
WO2013132477A1 (en) 2013-09-12
US20150044182A1 (en) 2015-02-12
US20180208888A1 (en) 2018-07-26
CN104245924A (zh) 2014-12-24
AU2013229008B2 (en) 2018-11-08
RU2014138001A (ru) 2016-04-20
AU2013229008A1 (en) 2014-09-18
CA2866358A1 (en) 2013-09-12
US9783778B2 (en) 2017-10-10
EP2823040A1 (en) 2015-01-14
EP2823040A4 (en) 2016-01-06
DK2823040T3 (en) 2018-11-19
IL234459B (en) 2020-02-27

Similar Documents

Publication Publication Date Title
Socié et al. Acute graft-versus-host disease: from the bench to the bedside
KR101518409B1 (ko) 단핵세포 증량 방법
KR102489954B1 (ko) 인간 백혈구 항원 제한된 감마 델타 t 세포 수용체 및 이의 사용 방법
JP5651583B2 (ja) 自己免疫疾患の治療および／または予防のための薬剤、ならびに制御性ｔ細胞形成のための薬剤
Boieri et al. The role of animal models in the study of hematopoietic stem cell transplantation and GvHD: a historical overview
KR101610353B1 (ko) Ｃｄｃａ１ 펩티드 및 이를 포함하는 약학적 조성물
IL270365B1 (en) Expansion of gamma delta t cells, compositions, and methods of use thereof
CN106029100A (zh) 在胃肠道移植物抗宿主病的治疗中使用il-22的方法
JP2020511531A (ja) 免疫調節機能を有するＦａｓＬ操作を受けた生体材料
US20180208888A1 (en) Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof
EP3303563B1 (en) Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof
KR20060040671A (ko) 단구성 기원의 자기 유래 자가 관용성 유도 세포 및약제학적 제제에 있어서의 이의 용도
KR20230019117A (ko) 개선된 백신 제제
Hainstock Characterization of an IL-7 Responsive, GM-CSF+ CD4+ T Cell Population That Promotes GI Inflammation in Acute GVHD
Jones The immunobiology of graft-versus-host disease across a minor histocompatibility antigen barrier

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20211005

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221024

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221024